Investment Rating - The report maintains a "Buy" rating for the company [6][3]. Core Insights - The company's annual performance met expectations, with commercial product sales slightly affected by price adjustments after inclusion in the medical insurance system. However, a strong recovery in growth is anticipated in 2026 [3][9]. - The company is confident that sales of its core product, Lukanosatuzumab, will double after its inclusion in the medical insurance system, with expected revenue from this product reaching 80% of its total income [9][3]. - The report highlights that several clinical and commercialization catalysts are expected in the short term, including the upcoming release of significant data for Lukanosatuzumab [9][3]. Financial Forecast Changes - Revenue projections for 2026 have been adjusted to USD 2.608 billion, a decrease of 14.1% from previous estimates. For 2027, revenue is projected at USD 4.193 billion, down 9.8% [4]. - Gross profit for 2026 is forecasted at USD 1.870 billion, reflecting a 16.4% reduction from prior estimates, with a gross margin of 71.7% [4]. - The net profit attributable to shareholders is expected to be a loss of USD 250 million in 2026, compared to a profit of USD 50 million previously forecasted [4]. Financial Data Summary - The company achieved a total revenue of RMB 2.058 billion in 2025, with a projected increase to RMB 2.608 billion in 2026 and RMB 4.193 billion in 2027 [15]. - The net loss for 2025 is projected to be RMB 527 million, with expectations of a return to profitability in 2027 with a net profit of RMB 485 million [15]. - The company’s cash and cash equivalents are expected to be RMB 3.060 billion by the end of 2026, increasing to RMB 5.202 billion by 2028 [15].

Investment Rating - The report maintains a "Buy" rating for WuXi AppTec (2268 HK) with a target price of HKD 91.00, indicating a potential upside of 62.1% from the current price of HKD 56.15 [1][5][11]. Core Insights - The company is expected to continue strong growth in 2025, with significant performance in financial metrics and order intake. A key turning point is anticipated in 2026 with a surge in M-end production projects, projecting a total of 30 BLA submissions from 2026 to 2028, which will drive new growth [2][7]. - The report highlights the company's competitive advantages in technology and service capabilities, particularly in the high-growth XDC CRDMO sector, and emphasizes the potential for market share expansion [2][5]. Financial Performance - For 2025, the company recorded a revenue increase of 46.7% and an adjusted net profit increase of 69.9%, aligning with previous forecasts [7]. - The gross margin improved significantly by 5.4 percentage points to 36.0%, attributed to enhanced capacity utilization and operational efficiency [7]. - The company anticipates revenue growth exceeding 40% in 2026, factoring in the consolidation of Dongya, with organic growth projected to surpass 35% [7]. Earnings Forecast Adjustments - The updated earnings forecasts for 2026-2028 show a slight increase in revenue projections, with 2026 revenue expected at RMB 8,331 million, a 1% increase from previous estimates [6]. - Adjusted net profit for 2026 is forecasted at RMB 2,173 million, reflecting a 5% decrease from prior estimates, while the adjusted net profit margin is expected to be 26.1% [6]. Market Position and Growth Drivers - The company signed a record 70 iCMC projects and added 10 PPQ projects in 2025, with a backlog of over USD 1.49 billion, indicating strong demand [7]. - The report notes that over 50% of new iCMC projects involve innovative coupling drugs, and the company is set to expand its production capacity significantly, including a new GMP facility in Singapore expected to commence operations in the second half of 2026 [7][8]. - Management projects that by 2030, revenue from XDC molecules and M-end projects will each account for 20% of total revenue [7].

Investment Rating - The investment rating for the company is "Outperform the Market" [7] Core Insights - The company experienced stable revenue growth of 1% year-on-year in 2025, with total revenue reaching 946 million yuan, while the GTV transaction amount decreased by 5% to 31,833 billion yuan. Non-housing business revenue accounted for 41% of total revenue, up 7 percentage points year-on-year [13][1] - Despite a decline in profits, the company increased shareholder returns, with total shareholder returns rising by 9% year-on-year in 2025 [25][2] - The company’s existing housing business showed stable performance, with transaction volume reaching a historical high, although GTV transaction value decreased by 4% to 21,515 billion yuan [49][3] - The new housing business saw a reduction in scale but an increase in contribution profit margin, with GTV transaction value down 8% to 8,909 billion yuan [82][4] - The non-housing business performed well, with new track business revenue increasing by 23% year-on-year to 390 billion yuan [111][5] Summary by Sections Revenue and Profitability - In 2025, the company achieved a net profit of 3 billion yuan, down 26% year-on-year, with an adjusted net profit of 5 billion yuan, down 30% [25][2] - The gross profit margin was 21%, a decrease of 3 percentage points year-on-year, while the contribution profit margin was 27%, down 3 percentage points [25][2] Business Segments - The existing housing business transaction volume increased by 11% year-on-year, but GTV transaction value decreased by 4% due to falling second-hand housing prices [49][3] - The new housing business's market share increased by 0.6 percentage points to 12.1%, despite a 9% decline in revenue [82][4] - The non-housing business, particularly home decoration and rental services, showed significant growth, with rental service revenue increasing by 53% year-on-year [111][5] Operational Efficiency - As of the end of 2025, the company had 61,000 stores, a 19% increase year-on-year, and 520,000 agents, a 5% increase year-on-year [135][10] - The company actively managed low-efficiency agents to maintain market share while reducing fixed costs [135][10] Future Outlook - The company revised its revenue forecasts for 2026 and 2027, expecting revenues of 888 billion yuan and 854 billion yuan, respectively, with adjusted net profits of 56 billion yuan and 61 billion yuan [152][12]

Investment Rating - The report maintains a "Buy" rating for the company [6][3]. Core Insights - The company's annual performance met expectations, with commercial product sales slightly affected by price adjustments after inclusion in medical insurance. However, a strong recovery in growth is anticipated in 2026 [3][9]. - The company is confident that sales of its core product, Lukanosatuzumab, will double after its inclusion in medical insurance, with expected revenue from this product accounting for over 80% of its total income [9][3]. - The report highlights upcoming key data releases for Lukanosatuzumab, with significant clinical and commercial catalysts expected in the short term [9][3]. Financial Forecast Changes - Revenue projections for 2026 have been adjusted to USD 2.608 billion, a decrease of 14.1% from previous estimates. For 2027, revenue is projected at USD 4.193 billion, down 9.8% [4]. - Gross profit for 2026 is forecasted at USD 1.870 billion, reflecting a 16.4% reduction from prior estimates, with a gross margin of 71.7% [4]. - The net profit attributable to shareholders is expected to be a loss of USD 250 million in 2026, compared to a profit of USD 50 million previously forecasted [4]. Financial Data Overview - The company achieved a total revenue of RMB 2.058 billion in 2025, with a projected increase to RMB 2.608 billion in 2026 and RMB 4.193 billion in 2027 [15]. - The net loss for 2025 is projected to be RMB 527 million, with expectations of a return to profitability in 2027 with a net profit of RMB 485 million [15]. - The company’s cash and cash equivalents are expected to be RMB 3.060 billion by the end of 2026, increasing to RMB 5.202 billion by 2028 [15].

Investment Rating - The report maintains a "Buy" rating for Horizon Robotics (9660.HK) [5] Core Insights - In 2025, the company achieved total revenue of 3.758 billion yuan, representing a year-on-year growth of 57.67%. However, the net profit attributable to the parent company was -10.469 billion yuan, a significant decline of 546.14% compared to the previous year [1][5] - The company holds a 47.7% market share in the ADAS market for domestic brands, leading the industry. In the mid-to-high-end intelligent driving market, it has a 14.4% market share, positioning itself among the top tier of the industry [1] - The company has seen a 38.8% year-on-year increase in the total shipment of its automotive-grade hardware, reaching 4.01 million units in 2025, with shipments supporting mid-to-high-end intelligent driving functions increasing to 4.8 times that of the same period in 2024 [2] Financial Performance - The projected revenue for 2026-2028 is estimated at 6.056 billion, 9.508 billion, and 14.737 billion yuan, respectively, with net profits expected to be -2.428 billion, -898.6 million, and 1.034 billion yuan [2][3] - The company’s earnings per share (EPS) for 2025 is projected at -0.7 yuan, with a price-to-earnings (P/E) ratio of -8.8 [3] - The gross margin is expected to be 65% in 2025, with a net margin of -279% [3]

Investment Rating - The investment rating for the company is maintained as "Buy" [7] Core Views - The company reported a revenue of 33.56 billion RMB for 2025, representing a year-on-year increase of 35.2%, and a net profit attributable to the parent company of 5.89 billion RMB, up 32.7% year-on-year, with a net profit margin of 17.5% [1][5] - The company continues to expand its store network, reaching a total of 59,823 stores by the end of 2025, a year-on-year increase of 28.7%, with strong domestic growth and adjustments in overseas operations to prepare for future growth [1][3] - The company is focusing on product upgrades and category expansion, which are expected to drive same-store sales optimization and improve operational quality [1][4] Summary by Sections Financial Performance - In 2025, the company achieved a gross margin of 31.1%, a decrease of 1.3 percentage points year-on-year, primarily due to changes in revenue structure and rising raw material costs [4] - The company’s revenue from merchandise and equipment sales reached 32.77 billion RMB, with a year-on-year growth of 35.3% [2] Store Expansion and Brand Development - The company has a total of 55,356 stores in mainland China and 4,467 overseas, with a net increase of 13,772 and a decrease of 428 stores respectively [3] - The company has successfully entered new markets such as Kazakhstan and the United States, while its sub-brand, Lucky Coffee, is accelerating its domestic expansion and exploring overseas opportunities [3] Management and Strategic Adjustments - The company announced a management restructuring aimed at enhancing operational efficiency and focusing on long-term strategic direction [4] - The new CEO is expected to drive the company towards internationalization and sustainable high-quality growth [4] Profit Forecast and Valuation - The forecast for net profit attributable to the parent company for 2026 is adjusted to 6.34 billion RMB, reflecting a decrease of 7.8% from previous estimates [5] - The target price is set at 473.52 HKD, based on a 25x PE ratio for 2026, down from a previous target of 590.22 HKD [5]

Investment Rating - The report maintains a "Strong Buy" rating for Nongfu Spring (09633.HK) with a target price of HKD 57 [2][7]. Core Insights - The company reported a revenue of HKD 52.553 billion for 2025, representing a year-on-year growth of 22.5%, and a net profit of HKD 15.868 billion, up 30.9% year-on-year [2][7]. - In the second half of 2025, the company achieved a revenue of HKD 26.931 billion, a 30% increase year-on-year, with a net profit of HKD 8.246 billion, reflecting a 40.2% growth [2][7]. - The company plans to distribute a cash dividend of HKD 0.99 per share, resulting in a payout ratio of 70.2% [2][7]. Financial Performance Summary - **Revenue and Profit Forecasts**: - 2025A Revenue: HKD 52.553 billion, 2026E: HKD 60.242 billion, 2027E: HKD 67.658 billion, 2028E: HKD 74.896 billion [2][11]. - 2025A Net Profit: HKD 15.868 billion, 2026E: HKD 17.636 billion, 2027E: HKD 19.856 billion, 2028E: HKD 22.320 billion [2][11]. - **Earnings Per Share (EPS)**: - 2025A: HKD 1.41, 2026E: HKD 1.57, 2027E: HKD 1.77, 2028E: HKD 1.98 [2][11]. - **Valuation Ratios**: - Price-to-Earnings (P/E) Ratio: 2025A: 26, 2026E: 24, 2027E: 21, 2028E: 19 [2][11]. - Price-to-Book (P/B) Ratio: 2025A: 10.6, 2026E: 9.6, 2027E: 8.5, 2028E: 7.5 [2][11]. Market Performance - The company’s market performance shows a significant recovery in the second half of 2025, with a notable increase in market share and revenue from various product lines, including packaged water and tea beverages [7][8]. - The gross margin for the second half of 2025 reached a historical high of 60.72%, benefiting from lower raw material costs and improved product mix [7][8].

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Insights - The company achieved total revenue of 2.058 billion yuan in 2025, representing a year-on-year increase of 6.5%. The revenue from drug sales surged by 949.8% to 543 million yuan, primarily due to the approval of new indications for its main products [8] - The commercialization of the core product, Sac-TMT, is progressing smoothly, with expectations for rapid growth as it covers over 30 provinces and 2,000 hospitals in China. Key indications have been included in the national medical insurance directory [8] - The company has a robust pipeline with multiple clinical trials ongoing, including four approved indications for Sac-TMT and several others in advanced stages. The ADC platform is also showing significant progress with multiple candidates entering clinical phases [8] Financial Summary - Total revenue projections for the company are 3.56 billion yuan in 2026, 5.89 billion yuan in 2027, and 7.66 billion yuan in 2028, indicating substantial growth rates of 72.99%, 65.56%, and 30.03% respectively [1][9] - The net profit is expected to turn positive by 2027, with a forecasted net profit of 649.8 million yuan, and further increasing to 1.62 billion yuan by 2028 [1][9] - The company maintains a strong cash position, with cash and financial assets exceeding 4.542 billion yuan, reflecting a 48% increase [8]

Investment Rating - The report maintains a "Buy" rating for China Power (2380 HK) with a target price of HKD 3.75, indicating an expected upside of 18.7% from the current price [4][8]. Core Insights - The company is focusing on balanced growth in installed capacity during the 14th Five-Year Plan, with an emphasis on shareholder returns [1]. - Despite a 13.5% year-on-year decline in profit for 2025, the company increased its final dividend by 3.7% to CNY 0.168 per share, raising the payout ratio to 70% [4]. - The company aims to increase the proportion of wind power installations while reducing solar power installations to below 30% by the end of the 14th Five-Year Plan [3]. Summary by Sections Financial Performance - For 2025, the company's revenue is projected to decline by 9.6% to CNY 49.03 billion, with operating profit decreasing by 1.9% to CNY 11.94 billion [5]. - The company expects to recover approximately CNY 6 billion in subsidies, a year-on-year increase of about CNY 4 billion, while capital expenditures are anticipated to decrease by CNY 10 billion [4]. - The overall limit electricity rate is around 9%, with wind and solar power limit rates at approximately 9% and 10.5%, respectively [4]. Operational Strategy - The company plans to add 6.2 GW of wind and solar capacity in 2025, with a focus on optimizing installation structure and regional layout [4]. - The management anticipates that the electricity supply situation will gradually improve with continued investments in ultra-high voltage and main grid infrastructure by the State Grid [4]. - The company aims for a full investment return requirement of 7.5%-9.5% for new wind and solar projects, with higher requirements in regions with severe electricity restrictions [3]. Segment Performance - The operating profit for thermal power is expected to increase by 4.9% to CNY 2.88 billion, while wind power profit is projected to decline by 10.6% to CNY 5.03 billion [6]. - The solar power segment is expected to see a significant drop in operating profit by 16.9% to CNY 3.07 billion [6]. - The storage business is projected to grow significantly, with an increase of 108.2% in operating profit [6].

Investment Rating - The report assigns a "Buy" rating for the company, indicating a potential upside in the stock price [5][6]. Core Insights - The company achieved a revenue of RMB 52.55 billion in 2025, representing a year-on-year growth of 22.5%, with a net profit of RMB 15.87 billion, up 30.9% year-on-year [6]. - The company’s diverse product portfolio includes 35.6% from packaged drinking water and 64.4% from beverages, with strong growth in both segments [2][6]. - The gross margin improved by 2.45 percentage points to 60.53%, primarily due to a decrease in procurement costs for PET, paper boxes, and sugar [8]. - The company plans to continue expanding its market share and product offerings while managing costs effectively, despite potential pressures from rising raw material prices [8]. Financial Summary - The company reported a net profit of RMB 15.87 billion for 2025, with projections for net profits of RMB 17.56 billion, RMB 19.56 billion, and RMB 21.35 billion for 2026, 2027, and 2028 respectively, reflecting growth rates of 10.7%, 11.4%, and 9.1% [10]. - Earnings per share (EPS) are projected to be RMB 1.576, RMB 1.74, and RMB 1.90 for the years 2026, 2027, and 2028, with corresponding price-to-earnings (P/E) ratios of 24x, 21x, and 20x [10][8]. - The company plans to distribute a cash dividend of RMB 0.99 per share for 2025, with expected increases in subsequent years [6][10].